Клофелин

Quick links to important sections

Клофелин

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Клофелин

Quick Facts

Property Description
Active ingredient Клонидина гидрохлорид (Clonidine hydrochloride)
Form Tablets, Solution for injection, Ophthalmic solution
Pharmacological class Central alpha2-adrenergic agonist, Antihypertensive agent
Common use Reduction of high blood pressure
Origin Synthetic imidazoline derivative

Клофелин (Clonidine): Classification and Chemical Identity

Клофелин is a medication derived from a synthetic compound classified chemically as an imidazoline derivative. Its therapeutic effect is attributable to the single active ingredient, Клонидина гидрохлорид (Clonidine hydrochloride), making it a monopreparat. Pharmacologically, it is designated as a central alpha2-adrenergic agonist, placing it among antihypertensive agents that primarily act on the central nervous system. This pharmacological classification is recognized for its direct influence on the autonomic nervous system. The medication's established importance in clinical settings is widely acknowledged.

Available Forms and General Therapeutic Purpose

To accommodate various patient needs, Клофелин is produced in several pharmaceutical preparations, including oral tablets, a sterile solution for injection for parenteral use, and an ophthalmic solution. The availability of the ophthalmic solution is a differentiating factor, allowing localized administration for specific eye conditions, separate from its systemic use. The drug's core therapeutic purpose is based on its ability to dampen stimulating signals from the sympathetic nervous system, which ultimately promotes the widening of blood vessels and a consequent drop in pressure. Clonidine acts on the central nervous system to decrease blood pressure. This action is central to its general benefit, which is the effective reduction of arterial hypertension, for instance, when rapid pressure stabilization is required, and the modulation of generalized discomfort associated with elevated nervous system activity.

Regulatory References

  1. Clonidine: MedlinePlus Drug Information

What side effects are possible with Клофелин?

Possible Side Effects and Safety Information

The safety profile for Clonidine (Клонидина гидрохлорид) is formally classified based on frequency and the body systems affected, according to official regulatory documentation. Most adverse effects are characterized as mild and may tend to diminish with continued therapy.

Adverse Reaction Scope

Classification Examples of Reactions
Very Common Dry mouth, drowsiness (somnolence), sedation, orthostatic hypotension.
Common Fatigue, headache, depression, sleep disorder, constipation, erectile dysfunction.
Uncommon Hallucination, syncope (fainting), pruritus, Raynaud's phenomenon.

Reactions are grouped into System-Organ Classes including Nervous System Disorders, Vascular Disorders, Psychiatric Disorders, and Gastrointestinal Disorders.

Serious Safety Considerations

A critical safety pattern relates to abrupt cessation of treatment, particularly after prolonged high-dose use, which may result in a severe withdrawal syndrome known as rebound hypertension. This is characterized by a rapid rise in blood pressure, potentially accompanied by symptoms such as nervousness and agitation. Rare, severe outcomes like hypertensive encephalopathy have been documented.

Population-Specific Notes

Caution is advised for patients with renal impairment due to the drug’s extensive renal excretion. Furthermore, the medication is generally contraindicated in individuals with severe bradyarrhythmia or pre-existing atrioventricular (AV) block of the 2nd or 3rd degree. Safety and effectiveness have not been definitively established for all formulations in the pediatric population.

Overdose and Emergency Response

The official regulatory documentation on Клофелин (Clonidine hydrochloride) overdose details severe manifestations primarily affecting the central nervous and cardiovascular systems.

Documented Clinical Manifestations

Overdose may present with profound Central Nervous System (CNS) depression, ranging from somnolence and drowsiness to coma. Significant cardiovascular compromise is a primary concern, involving severe hypotension (low blood pressure) and marked bradycardia (slow heart rate). Other documented signs include miosis (pinpoint pupils) and hypothermia (abnormally low body temperature). Life-threatening outcomes include respiratory arrest.

Mandated Emergency Actions

Due to the potential for rapid onset of severe, life-threatening symptoms, official government guidance requires the user to seek immediate medical attention and contact emergency services for any suspected ingestion beyond the prescribed amount. Treatment is explicitly defined as symptomatic and supportive, requiring continuous monitoring of vital signs and cardiac function (ECG/EKG) in a hospital setting. No specific antidote is formally known, though certain pharmacological interventions may be considered by medical professionals for supportive care.

Population-Specific Risk

Regulatory sources highlight that overdose is particularly dangerous in pediatric patients (children), where relatively minor ingestion or dosing errors have been documented to result in severe toxicity, including coma and respiratory compromise. The need for urgent professional medical assessment is critical in this population.

Therapeutic Uses of Клофелин

What Клофелин Treats: Main Uses and Benefits

The core therapeutic areas of Clonidine (Клофелин) span cardiovascular, neurological, and symptomatic relief domains. These therapeutic applications are established within clinical practice. This range of use is relevant in contexts marked by increased discomfort or tension across various systemic functions.

This medication is commonly used to help manage symptoms related to systemic hypertension (high blood pressure) and is applicable in conditions involving episodic or fluctuating manifestations like Attention Deficit Hyperactivity Disorder (ADHD). It is also relevant for easing acute distress during substance withdrawal and for providing support against disruptive menopausal hot flashes.

“It provides supportive relief when symptoms interfere with routine activities, which may assist with easing distress.”

Quick Fact: Support for Symptoms of Systemic Hyperactivity

This medication is relevant for easing symptoms related to heightened physiological activity and neurological over-stimulation, applied in settings where symptomatic assistance is appropriate. Its use may assist with managing symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Клофелин? — Official Regulatory Information

The eligibility for Clonidine (Клофелин) is defined by strict regulatory guidelines regarding pre-existing medical conditions, patient age, and physiological status.

Contraindicated Populations

Use of Clonidine is absolutely contraindicated in patients with a known hypersensitivity to clonidine hydrochloride or any component of the formulation. It is also prohibited for patients experiencing severe bradyarrhythmia resulting from conditions such as sick sinus syndrome or second or third-degree atrioventricular (AV) block.

Age- and Condition-Based Restrictions

Category Official Regulatory Status
Pediatric Use (Hypertension) Safety and effectiveness are not established for general antihypertensive treatment.
Children under 6 years Safety for specific extended-release formulations is not established.
Renal Impairment Requires caution and monitoring due to impact on drug clearance.
Pregnancy Classified as Category C; use is restricted to situations where benefit justifies potential risk.
Lactation Not recommended due to drug excretion into human milk.
Cardiovascular Risk Use requires caution in patients with conditions like severe coronary insufficiency or recent myocardial infarction.

These official rules strictly delineate the patient groups for whom the medicine is prohibited or necessitates careful clinical oversight.

What should I know about interactions with other medicines?

The official regulatory documents categorize the interactions of Clonidine (Клофелин) primarily as pharmacodynamic, focusing on additive effects within the central nervous and cardiovascular systems.

Interactions Affecting Function

Co-administration with substances that possess central nervous system (CNS) depressive properties may potentiate the sedative effects of Clonidine. This category includes alcohol, barbiturates, and other sedating medications. The official profile also identifies a potential for additive cardiac effects when Clonidine is used concomitantly with agents known to affect sinus node function or atrioventricular (AV) nodal conduction.

Such agents include digitalis (cardiac glycosides), calcium channel blockers, and beta-blockers, which may lead to combined outcomes like bradycardia and AV block. No formal contraindications based solely on drug-drug interaction risk are stated in major US or EU labeling.

Effects on Drug Action and Timing

A counter-effect interaction is documented with Tricyclic Antidepressants (TCAs), which may reduce the antihypertensive effect of Clonidine. This documented antagonism may necessitate an increase in the Clonidine dose to maintain the intended therapeutic outcome. A specific procedural constraint governs the discontinuation process for patients receiving both Clonidine and a beta-blocker: the beta-blocker must be withdrawn several days prior to the gradual cessation of Clonidine. This necessary sequencing is noted in official documents due to an increased likelihood of withdrawal reactions when these two types of medicine are stopped together.

Mechanism of Action

Central Regulation of Sympathetic Outflow

The primary mechanism involves Клонидина гидрохлорид acting as an agonist on alpha2-adrenergic receptors and imidazoline I1 receptors located in the brainstem's vasomotor centers. Activating these central targets effectively suppresses the release of the stimulating neurotransmitter norepinephrine and reduces the firing of preganglionic neurons, resulting in reduced activity of the sympathetic nervous system .


Pathway-Level Consequences and Systemic Effect

This central suppression initiates a cascade of downstream effects: reduced sympathetic tone leads to vasodilation (widening of blood vessels) and a decrease in heart rate and cardiac output. These actions collectively lower the body's systemic vascular resistance and contribute to a reduction in systemic vascular resistance and heart rate. Additionally, this mechanism modulates central norepinephrine activity, which modulates central pathways involved in noradrenergic regulation of central nervous system excitability.


Mechanistic Boundaries and Constraints

While the central effect dominates, the mechanism is subject to constraints, including the potential for receptor desensitization with chronic use, which can lead to a reduced magnitude of sympathetic suppression over time. Crucially, the abrupt discontinuation of the drug can unmask previously suppressed sympathetic activity, resulting in a temporary hyperadrenergic state due to unmasking of previously suppressed sympathetic activity and altered receptor responsiveness.

Dosage and Administration Information

Official Administration Guidelines

Clonidine (Клофелин) is administered through multiple routes, including oral (immediate-release or extended-release tablets and solutions), transdermal (a patch applied once weekly), and specialized parenteral routes, such as continuous epidural infusion.

For oral immediate-release (IR) tablets, the typical adult regimen begins with 0.1 mg taken two times per day. The maintenance range commonly spans 0.2 mg to 0.6 mg total daily, taken in divided doses. The total daily dose of oral forms should be adjusted in small increments (e.g., 0.1 mg per day) at weekly intervals until the required pattern is achieved. The medication can be taken with or without food.

Formulation-specific instructions are mandatory: Extended-release tablets must be swallowed whole and not crushed, broken, or chewed. Patients with renal impairment or older adults may require a lower initial dose and slower titration due to altered pharmacokinetics. Extended-release formulations are not to be substituted for immediate-release forms on a milligram-per-milligram basis.

Time-related management is critical: therapy must never be stopped abruptly. The dose must be gradually tapered over several days (e.g., 3 to 7 days) to prevent rebound effects. If a dose is missed, the standard approach is to skip the missed dose and continue with the next scheduled dose; doubling the dose is not permitted.

Recent Clinical Evidence

Клофелин: Recent Clinical Evidence

Clonidine (known historically by the Russian transliteration Клофелин) is a centrally acting alpha-2 adrenergic agonist primarily approved for the treatment of hypertension (high blood pressure). It acts by stimulating alpha-2 receptors in the brain, which results in reduced sympathetic outflow and lowered heart rate and blood pressure.


Approved and Investigational Uses

Beyond its original use in hypertension, clinical research supports its role in several other therapeutic areas, with extended-release formulations approved by some regulatory bodies for conditions such as Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Its pharmacological properties, including sedative and analgesic effects, have led to various applications that are sometimes considered off-label, such as managing symptoms of opioid and alcohol withdrawal and managing certain types of chronic pain.


Key Clinical Findings

Recent and historical evidence from randomized controlled trials (RCTs) and systematic reviews highlight specific applications:

  • Resistant Hypertension: A large comparative trial (ReHOT study) found that clonidine achieved similar rates of blood pressure control to spironolactone when added as a fourth-line drug for resistant hypertension, although overall control rates for both were low.
  • ADHD in Youth: Multiple double-blind, placebo-controlled trials have reported observations of symptom improvement in children and adolescents with ADHD, both as monotherapy and when used adjunctively with stimulants.
  • Impulse Control Disorders (ICDs): Early-phase trials in participants with Parkinson's disease explored the agent's effects on ICDs. While one Phase 2b trial showed a numerically greater reduction in total symptom scores for the clonidine group compared to placebo at eight weeks, the study lacked sufficient power to demonstrate statistical superiority.

Safety Profile

The most commonly reported adverse events across studies include sedation, dry mouth, dizziness, and hypotension (low blood pressure). Abrupt discontinuation is known to cause rebound hypertension and related withdrawal symptoms, emphasizing the need for professional guidance during treatment changes.

Key Studies & References

  1. Clonidine - StatPearls (for general safety and mechanism summary)

Frequently Asked Questions (FAQ)

Common questions about Клофелин (FAQ)


Q: How quickly does Клофелин start to work after taking it?

The immediate-release form begins to reduce blood pressure within 30 to 60 minutes after being taken. According to official regulatory documents, the maximum reduction in pressure typically occurs within 2 to 4 hours.


Q: What is the expected duration of the effects of Клофелин?

For the immediate-release oral form, the blood pressure-lowering effect generally lasts between 6 to 12 hours. This duration explains why this formulation is typically prescribed to be taken more than once daily.


Q: Can Клофелин interact with over-the-counter pain relievers like ibuprofen?

Official drug guidance reports that non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the effectiveness of Clonidine. Taking these two types of medicines together could potentially make the blood pressure medicine less effective.


Q: Are there any known issues with taking Клофелин before or after surgery?

Official guidance notes that the drug’s administration is often maintained until up to four hours before surgery and resumed as soon as possible after. Close monitoring of blood pressure during and after surgery is described as necessary.


Q: What should I do if a side effect of Клофелин seems severe?

Official information describes the potential symptoms of serious adverse events, such as a very rapid rise in blood pressure (known as rebound hypertension). Official guidance states that if a severe reaction is suspected, patients should contact emergency medical services.


Q: Can I take other supplements or vitamins while using Клофелин?

Official product labeling contains a general statement encouraging patients to review all vitamins, herbs, and supplements with a healthcare provider. This is because some supplements have the potential to affect blood pressure and heart rate, which could interact with Clonidine's effects.


Q: Are generic versions of Клофелин available, and are they equivalent?

Generic versions of Clonidine are available. However, official documents caution against substituting an immediate-release form for an extended-release form on a milligram-per-milligram basis, as these two types have different release profiles and effects.


Q: What are the signs of a potential interaction with Клофелин?

Signs of a potential interaction or severe reaction described in official documents include symptoms of excessive central nervous system effects, such as a very slow heart rate or excessive drowsiness and sedation. Symptoms of very low blood pressure, like dizziness or feeling faint, may also signal a problem.


Q: Do I need any special tests or checks before starting Клофелин?

Official guidance indicates that heart rate and blood pressure measurements are generally taken before treatment is started, following any dose changes, and at periodic intervals during therapy.


Q: What are the signs of taking too much Клофелин?

Official documents describe the signs of taking too much medicine. These include a rapid increase in blood pressure which is quickly followed by severe low blood pressure, a very slow heart rate, difficulty breathing, and excessive drowsiness.


Q: Is Клофелин the same type of medicine as regular blood pressure pills?

Official classification labels Clonidine as a centrally acting alpha-agonist antihypertensive agent. This means that unlike many common blood pressure medicines that act directly on the heart or vessels, its primary action to lower blood pressure occurs by reducing nerve signals from the central nervous system (brain).


Q: Are there any specific foods or drinks to avoid while using Клофелин?

Official regulatory labeling specifically warns that consuming alcohol can increase the sedative effects of the medicine. Otherwise, the medicine can generally be taken with or without food.


Q: Does taking Клофелин affect my ability to drive or operate machinery?

Official warnings note that due to the very common side effects of drowsiness and dizziness, activities requiring alertness, such as driving or operating heavy machinery, should be approached with caution, especially when first starting therapy.


Q: What is the main difference between Клофелин and other alpha-blockers?

Clonidine is a type of alpha-agonist that works primarily in the brain (centrally) to reduce nerve activity. Other types of alpha-blockers often work peripherally, meaning they affect the blood vessels directly to cause widening.


Q: What does the research say about the long-term use of Клофелин?

The official labeling mentions that some patients may develop tolerance to the blood pressure-lowering effect during long-term use. If this occurs, a reevaluation of the overall therapy may be necessary.


Q: Is it necessary to monitor blood pressure closely when starting Клофелин?

Official product labeling indicates that heart rate and blood pressure measurements are generally taken before starting treatment and following dose adjustments to help achieve the desired effect and prevent pressure from dropping too low.


Q: Does Клофелин interact with commonly prescribed anxiety medications?

Regulatory information warns of increased sedative effects when Clonidine is taken with other central nervous system (CNS) depressant drugs. This category includes certain types of commonly prescribed anxiety and sleep medications.


Q: Is there any difference in effect if I take Клофелин in the morning versus the evening?

Since drowsiness and sedation are described as very common side effects, dosing protocols often involve giving a split dose or the larger portion of the dose at bedtime. This practice helps to minimize the intensity of the daytime drowsiness.


Q: Is it safe to take two different blood pressure medicines at the same time as Клофелин?

Official documents note that caution is generally warranted when Clonidine is combined with other blood pressure or heart rate lowering medicines, due to the risk of potentially additive effects such as low blood pressure or a significantly slow heart rate.


Q: What is the difference between immediate-release and extended-release forms of Клофелин?

The immediate-release form provides a shorter duration of effect and is typically taken multiple times per day. In contrast, the extended-release form is designed to work continuously over a full day and is often taken only once daily.


Q: How does the action of Клофелин compare to diuretics for high blood pressure?

Clonidine lowers blood pressure by reducing signals from the central nervous system to the blood vessels. This differs from diuretics, which typically work on the kidneys to help the body excrete excess salt and water.


Q: Are there any demographic groups where Клофелин is studied less?

Official regulatory information states that the safety and effectiveness for using Clonidine to treat high blood pressure have not been definitively established for the general pediatric population (children).

How should Клофелин be stored and disposed of?

How to Store and Dispose of Clonidine

Official regulatory information for clonidine storage and disposal focuses on maintaining drug stability and preventing accidental exposure.

Storage Conditions Requirements
Temperature Store tablets at Controlled Room Temperature (20 C to 25 C), protecting from excessive heat and moisture.
Container & Handling Keep medication in the tightly closed original container. Protect the tablets from light. Do not freeze or refrigerate the oral solution.
Child Safety Store strictly out of sight and reach of children, as many containers are not child-resistant.
Stability Discard single-use injections immediately after use. Discard multi-dose oral solutions after the specified in-use period (30 or 60 days) following the first opening.
Disposal The preferred method is to return unused or expired medicine to a drug take-back program. If a program is unavailable, mix the medicine with an unappealing substance (like dirt), seal it in a bag, and dispose of it in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Клофелин found in:

A-Z Index: